MEN1 and acute myeloid leukemia: Additionally menin complex inhibitors downregulated and dephosphorylated FLT3, FLT3-ITD inhibitor and menin inhibitor combination therapy led to a left shift of the 50% inhibitory concentration for combination components over the individual drugs, and a murine model of KMT2A-rearranged FLT3-ITD mutated AML showed improved survival [61,62].